<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03381274</url>
  </required_header>
  <id_info>
    <org_study_id>D6070C00004</org_study_id>
    <nct_id>NCT03381274</nct_id>
  </id_info>
  <brief_title>MEDI9447 EGFRm NSCLC Novel Combination Study</brief_title>
  <official_title>A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced EGFRm NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the safety, tolerability and antitumor activity
      of novel combination therapies administered in subjects with advanced EGFRm NSCLC
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2018</start_date>
  <completion_date type="Anticipated">January 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 13, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events as a measure of safety</measure>
    <time_frame>Screening through 90 days after last dose of investigational product</time_frame>
    <description>The primary endpoint is safety as assessed by the presence of adverse events and serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate as a measure of anti tumor activity in dose expansion phase</measure>
    <time_frame>During treatment through study completion, about 2 years after the last subject dosed</time_frame>
    <description>The primary endpoint in dose expansion phase includes efficacy assessed by objective response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>During treatment through study completion, about 2 years after the last subject dosed</time_frame>
    <description>The duration from the first documentation of objective response (OR) to the first documented disease progression or death due to any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control (DC)</measure>
    <time_frame>During treatment through study completion, about 2 years after the last subject dosed</time_frame>
    <description>Defined as complete response (CR), partial response (PR) or stable disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>During treatment through study completion, about 2 years after the last subject dosed</time_frame>
    <description>From the start of treatment with investigational product until the first documentation of disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>During treatment through study completion, about 2 years after the last subject dosed</time_frame>
    <description>From the start of treatment with investigational product until death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response by T790M status</measure>
    <time_frame>During treatment through study completion, about 2 years after the last subject dosed</time_frame>
    <description>Defined as best overall response of confirmed CR or confirmed PR according to RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control by T790M status</measure>
    <time_frame>During treatment through study completion, about 2 years after the last subject dosed</time_frame>
    <description>Defined as CR, PR or SD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum MEDI9447 concentration levels</measure>
    <time_frame>During treatment through 90 days after last dose of investigational product</time_frame>
    <description>Pharmacokinetic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Osimertinib concentration levels</measure>
    <time_frame>During treatment through 90 days after last dose of investigational product</time_frame>
    <description>Pharmacokinetic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum AZD4635 concentration levels</measure>
    <time_frame>During treatment through 90 days after last dose of investigational product</time_frame>
    <description>Pharmacokinetic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of detectable anti-drug antibody(ADA) to MEDI9447</measure>
    <time_frame>During treatment through 90 days after last dose of investigational product</time_frame>
    <description>Immunogenicity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI9447 and osimertinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI9447 and AZD4635</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI9447</intervention_name>
    <description>Subjects will receive MEDI9447 in combination with osimertinib or AZD4635 until disease progression</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osimertinib</intervention_name>
    <description>Subjects will receive osimertinib in combination with MEDI9447 until disease progression</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD4635</intervention_name>
    <description>Subjects will receive AZD4635 in combination with MEDI9447 until disease progression</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18

          2. ECOG Performance Status of 0 or 1

          3. Weight ≥ 35 kg

          4. Diagnosed with histologically or cytologically confirmed locally advanced/metastatic
             NSCLC with EGFR mutation

               -  For Arm A: must have received 1 prior line of therapy with an EGFR TKI and
                  confirmed T790M negative

               -  For Arm B: must have received at least 2 but not more than 3 prior lines of
                  therapy.

        Exclusion Criteria:

          1. Receipt of an EGFR TKI within 14 days of the first dose of study treatment.

          2. Receipt of any conventional or investigational anticancer therapy not otherwise
             specified within 21 days of the planned first dose.

          3. Prior receipt of any investigational immunotherapy. Subjects may have received agents
             that have local health authority approval for the disease indication

          4. Concurrent enrollment in another therapeutic clinical study. Enrollment in
             observational studies will be allowed

          5. Subjects with a history of venous thrombosis within the past 3 months

          6. Subjects with prior history of myocardial infarction, transient ischemic attack, or
             stroke in the last 6 months

          7. Active or prior documented autoimmune or inflammatory disorders within the past 3
             years prior to the start of treatment

          8. Other invasive malignancy within 2 years.

          9. Untreated CNS metastatic disease, leptomeningeal disease, or cord compression

         10. Current or prior use of immunosuppressive medication within 14 days prior to the first
             dose

        Additional Exclusion Criteria for Arm A

          1. Concurrent treatment (or inability to stop therapy) with medications or herbal
             supplements known to be potent inducers of CYP3A4

          2. Subject has a history of ILD, drug-induced ILD, radiation pneumonitis that required
             steroid treatment, or any evidence of clinically active ILD.

          3. Subject requires supplemental oxygen for any reason.

        Additional Exclusion Criteria for Arm B

          1. Herbal preparations/medications are not allowed throughout the study

          2. History of seizures, prior traumatic brain injury, prior stroke, or other predisposing
             risk of seizure (excluding CNS metastasis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MedImmune LLC</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>AstraZeneca Cancer Study Locater Service</last_name>
    <phone>1-877-400-4656</phone>
    <email>AstraZeneca@emergingmed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2017</study_first_submitted>
  <study_first_submitted_qc>December 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2017</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AZ's policy is to share data with researchers if the request is in scope of our policy. The policy and additional information can be found on astrazenecaclinicaltrials.com.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

